Quick Answer
ANI PHARMACEUTICALS INC reported Total Revenue of $883.37 million for fiscal year 2025.
ANI PHARMACEUTICALS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $883.37M +43.8% |
$614.38M +26.2% |
$486.82M +53.9% |
$316.38M +46.4% |
$216.14M +3.7% |
$208.47M +0.9% |
| Revenue (ASC 606) | $883.37M +43.8% |
$614.38M +26.2% |
$486.82M +53.9% |
$316.38M +46.4% |
$216.14M +3.7% |
$208.47M +0.9% |
| Net Income | $78.34M +522.9% |
-$18.52M -198.6% |
$18.78M +139.2% |
-$47.90M -12.4% |
-$42.60M -88.9% |
-$22.55M -470.0% |
| Diluted EPS | $3.32 +419.2% |
-$1.04 -222.4% |
$0.85 +127.9% |
-$3.05 +10.3% |
-$3.40 -80.9% |
-$1.88 -476.0% |
| Total Assets | $1.44B +12.1% |
$1.28B +42.0% |
$904.42M +19.0% |
$760.09M -1.5% |
$771.60M +67.3% |
$461.19M +1.0% |
| Cash and Equivalents | $285.58M +97.1% |
$144.86M -34.5% |
$221.12M +358.5% |
$48.23M -51.9% |
$100.30M +1175.4% |
$7.86M -87.4% |
| Long-Term Debt | $291.84M -5.6% |
$309.11M +8.5% |
$284.82M -0.3% |
$285.67M -0.3% |
$286.52M +66.2% |
$172.44M -1.9% |
| Stockholders Equity | $540.72M +33.9% |
$403.68M -6.7% |
$432.75M +38.0% |
$313.69M -6.0% |
$333.89M +70.6% |
$195.70M -8.0% |
| R&D Expense | $51.66M +15.9% |
$44.58M +30.0% |
$34.29M +53.6% |
$22.32M +96.3% |
$11.37M -28.9% |
$16.00M -19.2% |
| Operating Income | $111.09M +18922.8% |
$584.0K -98.8% |
$46.97M +233.1% |
-$35.28M +11.3% |
-$39.79M -148.5% |
-$16.02M -198.0% |
| Shares Outstanding | 22.49M +6.6% |
21.11M | — | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $227.81M | +53.6% | +7.8% |
| Revenue (ASC 606) | September 30, 2025 | $227.81M | +53.6% | +7.8% |
| Net Income | September 30, 2025 | $26.62M | +210.1% | +211.3% |
| Diluted EPS | September 30, 2025 | $1.13 | +189.0% | +213.9% |
| Total Assets | September 30, 2025 | $1.41B | +9.4% | +4.9% |
| Cash and Equivalents | September 30, 2025 | $262.61M | +81.1% | +20.6% |
| Long-Term Debt | September 30, 2025 | $297.68M | -4.9% | -1.3% |
| Stockholders Equity | September 30, 2025 | $505.82M | +24.6% | +15.8% |
| R&D Expense | September 30, 2025 | $12.30M | +21.5% | -25.6% |
| Operating Income | September 30, 2025 | $36.24M | +276.6% | +160.9% |
- ANI PHARMACEUTICALS INC reported Total Revenue of $883.37 million for fiscal year 2025.
- ANI PHARMACEUTICALS INC showed an increase of +43.8% in Total Revenue compared to the prior fiscal year.
- ANI PHARMACEUTICALS INC reported Revenue (ASC 606) of $883.37 million for fiscal year 2025.
- ANI PHARMACEUTICALS INC showed an increase of +43.8% in Revenue (ASC 606) compared to the prior fiscal year.
- ANI PHARMACEUTICALS INC reported Net Income of $78.34 million for fiscal year 2025.
- ANI PHARMACEUTICALS INC showed an increase of +522.9% in Net Income compared to the prior fiscal year.
- ANI PHARMACEUTICALS INC reported Diluted EPS of $3.32 per share for fiscal year 2025.
- ANI PHARMACEUTICALS INC showed an increase of +419.2% in Diluted EPS compared to the prior fiscal year.
- ANI PHARMACEUTICALS INC reported Total Assets of $1.44 billion for fiscal year 2025.
- ANI PHARMACEUTICALS INC showed an increase of +12.1% in Total Assets compared to the prior fiscal year.
- ANI PHARMACEUTICALS INC reported Cash and Equivalents of $285.58 million for fiscal year 2025.
- ANI PHARMACEUTICALS INC showed an increase of +97.1% in Cash and Equivalents compared to the prior fiscal year.
- ANI PHARMACEUTICALS INC reported Long-Term Debt of $291.84 million for fiscal year 2025.
- ANI PHARMACEUTICALS INC showed a decrease of -5.6% in Long-Term Debt compared to the prior fiscal year.
- ANI PHARMACEUTICALS INC reported Stockholders Equity of $540.72 million for fiscal year 2025.
- ANI PHARMACEUTICALS INC showed an increase of +33.9% in Stockholders Equity compared to the prior fiscal year.
- ANI PHARMACEUTICALS INC reported R&D Expense of $51.66 million for fiscal year 2025.
- ANI PHARMACEUTICALS INC showed an increase of +15.9% in R&D Expense compared to the prior fiscal year.
- ANI PHARMACEUTICALS INC reported Operating Income of $111.09 million for fiscal year 2025.
- ANI PHARMACEUTICALS INC showed an increase of +18922.8% in Operating Income compared to the prior fiscal year.
- ANI PHARMACEUTICALS INC reported Shares Outstanding of 22.49 million shares for fiscal year 2025.
- ANI PHARMACEUTICALS INC showed an increase of +6.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: